ACCENGAGE/URBAN-AIRSHIP
Accengage , an Urban Airship company and Europe’s #1 mobile CRM and push notification technology provider, today announced that it is adding WhatsApp as one of its customer engagement channels. Brands can now engage with prospects and customers using push notifications and automated replies through the WhatsApp Business API. To make it even more powerful and easy to use, the new solution leverages the full power of Accengage’s UI for segmentation, personalization, localized languages and connections with other business systems.
As a WhatsApp Business solution provider, Accengage enables enterprises to send personalized WhatsApp messages and interact with their global customer bases at immense scale.
Businesses using Accengage can send non-promotional notifications and automated replies to WhatsApp users who have explicitly given their consent. Such WhatsApp notifications can include status updates on deliveries or flight times, proactive reminders or transactional details following a booking or an order, as well as requests for customer feedback.
This new Accengage channel opens up even more potential solutions that combine Accengage and Urban Airship technologies. New capabilities like being able to create a personalized loyalty card, coupon or mobile boarding pass or ticket using Urban Airship, and deliver it to customers on WhatsApp via Accengage, are receiving strong interest from international companies across retail, travel and entertainment industries.
“With more than 1.5 billion users across 180 countries, WhatsApp offers businesses a rare opportunity to engage more of their customers with meaningful and impactful experiences,” said Patrick Mareuil, former CEO and co-founder of Accengage, now managing director of EMEA at Urban Airship. “We are already seeing fantastic interest from businesses around the world interested in adding WhatsApp as a channel to reach more prospects and customers in moments that really matter to them.”
About Accengage, an Urban Airship Company
Founded in 2010, Accengage is Europe’s leading Push Notification & Mobile CRM Technology for Mobile Apps, Websites, Facebook Messenger and WhatsApp.
In January 2019, Accengage was acquired by Urban Airship to create the world’s leading digital customer engagement company. Together, the combined company provides the technology to create magical customer experiences via push notifications, in-app messaging, SMS, email, messaging apps, mobile wallets and other channels.
Accengage empowers marketers in more than 70 countries to boost customer engagement, conversion and retention. The company sends over 10 billion push notifications monthly to 900 million customers worldwide for hundreds of brands . To learn more about Accengage, please visit: www.accengage.com .
About the Accengage solution for WhatsApp Notifications
Accengage provides the WhatsApp Business API as part of its SaaS technology. Businesses have access to the Accengage user interface where they can create segments, set up messages, send WhatsApp notifications and analyze performance. Some of the features available now include the support of multilingual messages, personalization, automation and interconnection to external CRM & marketing solutions. Multilingual support and customer success teams are available to onboard new customers and train them on the new channel.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190327005071/en/
Contact:
UK: Lucinda Layton Hotwire UK +44 20 7608 2500 UrbanAirship@hotwireglobal.com
France: Sarah Amsellem Arbre / Marine Cressot Hotwire France +33 14 312 55 53 / 69 UrbanAirshipFR@hotwireglobal.com
Nicolas Vitre Urban Airship +33 1 44 56 88 21 +33 6 88 04 76 86 nicolas.vitre@urbanairship.com
Germany: Julia da Silva Bastos Hotwire Germany +49 89 2620 81 89 urbanairshipDE@hotwireglobal.com
Italy: Sara Tetti Hotwire Italy Number UrbanAirshipIT@hotwireglobal.com
Spain: Beatriz Pérez Hotwire Spain +34 917 44 1265 beatriz.perez@hotwireglobal.com
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Vertex Receives CHMP Positive Opinion for ALYFTREK®, a New Once-Daily CFTR Modulator for the Treatment of Cystic Fibrosis28.4.2025 08:03:00 CEST | Press release
- ALYFTREK®(deutivacaftor/tezacaftor/vanzacaftor) recommended for people with CF ages 6 years and older with at least one non-class I mutation in the CFTR gene -- In head-to-head clinical trials, deutivacaftor/tezacaftor/vanzacaftor was non-inferior on ppFEV1 and superior compared to KAFTRIO® (ivacaftor/tezacaftor/elexacaftor) at reducing sweat chloride - Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for ALYFTREK®(deutivacaftor/tezacaftor/vanzacaftor)for the treatment of people with cystic fibrosis (CF) ages 6 years and older who have at least one non-class I mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. “Our goal has always been to serially innovate to help people with cystic fibrosis live healthier and longer lives. If approved, this new medicine would be indicated for people with CF ages 6 years and older with at least
Prilenia Enters into a Collaboration and License Agreement with Ferrer for the Commercialization and Co-Development of Pridopidine in Europe and Other Select Markets28.4.2025 07:02:00 CEST | Press release
-- Total deal size of approximately €500 million, including approximately €125 million in upfront and near-term milestones ---- Ferrer to commercialize pridopidine in Europe and other select markets; Prilenia retains full commercialization and development rights to pridopidine in North America, Japan and Asia Pacific ---- Co-development agreement in the territory supports further expansion of pridopidine in Huntington’s disease, amyotrophic lateral sclerosis and future indications ---- Pridopidine for Huntington’s disease is currently under review by the European Medicines Agency (EMA) with a CHMP opinion expected in the second half of 2025 -- Prilenia Therapeutics B.V., a biopharmaceutical company driven by an unwavering commitment to scientific excellence and accelerating progress for people affected by Huntington’s disease (HD) and amyotrophic lateral sclerosis (ALS), today announced that it has entered into a collaboration and license agreement with Ferrer for the commercialization
Ferrer Enters Into a Collaboration and License Agreement With Prilenia for the Commercialization and Co-Development of Pridopidine28.4.2025 07:00:00 CEST | Press release
Ferrer, an international B Corp pharmaceutical company with an increasing focus on rare neurological diseases, and Prilenia Therapeutics B.V.,a clinical-stage biotech company, have announced the signing of a strategic co-development and license agreement in which Ferrer obtains the rights to develop, manufacture and commercialize Pridopidine in the European Region, the Middle East and North African Region, the Southern African Region, the Central and South American Region, and the Commonwealth of Independent States Region. Pridopidine, a potent and highly selective, orally administered sigma-1 receptor agonist, designed to regulate key neuroprotective mechanisms that are often impaired in neurodegenerative diseases, is a promising candidate for the treatment of Huntington’s Disease (HD), a rare inherited neurodegenerative disease, with a high unmet medical need1. It has been studied in more than 1,700 people and long-term safety data of up to 7 years duration are available from previou
Innorna Announces FDA Rare Pediatric Disease and Orphan Drug Designations Granted to IN013 for Treatment of Wilson Disease27.4.2025 11:36:00 CEST | Press release
Innorna, a clinical-stage biotechnology company revolutionizing mRNA therapeutics with its innovative lipid nanoparticle (LNP) delivery technology, today announced the U.S. Food and Drug Administration (FDA) has granted both Rare Pediatric Disease Designation (RPDD) and Orphan Drug Designation (ODD) to its investigational mRNA therapy, IN013, for treating Wilson Disease (WD). This dual achievement accelerates the clinical development of IN013, advancing Innorna’s mission to deliver transformative therapies for WD patients. About FDA Designations The Rare Pediatric Disease Designation (RPDD) incentivizes therapies for serious or life-threatening diseases affecting fewer than 200,000 U.S. patients, primarily those aged 18 or younger. Sponsors may qualify for a Priority Review Voucher (PRV) upon approval to expedite FDA review of a subsequent drug application. The Orphan Drug Designation (ODD) supports therapies targeting rare diseases (affecting fewer than 200,000 U.S. patients) by provi
Everen Specialty Appoints Carla Greaves Chief Underwriting Officer25.4.2025 19:00:00 CEST | Press release
Everen Specialty, a Bermuda-based (re)insurer for energy markets worldwide, today announced the appointment of Carla Greaves as its new Chief Underwriting Officer (CUO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250425273777/en/ Carla Greaves Ms. Greaves will join the Executive Leadership Team of the Everen Group, based in the Bermuda office, later this year. She succeeds Jane Peterson, Interim CUO, who will continue in a consultancy capacity to facilitate the transition. With more than 30 years of underwriting and leadership experience in the (re)insurance industry, Ms. Greaves brings a wealth of expertise and a proven track record of success in the Casualty market where she is recognized for building high-performing teams, driving profitable growth, and successfully navigating complex market environments. Prior to joining Everen Specialty, Ms. Greaves held increasingly senior leadership positions, most recently servin
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom